Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Maja Agung Latexindo TbkISX:SURI +4.00%53 EV-to-EBITDA is 290.81 as of Aug. 16, 2026, which is 356% above its 10-year median of 63.77. GuruFocus rates ISX:SURI with a GF Score™ of 53/100 and a GF Value™ of Rp107.24 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 513 Medical Devices & Instruments companies, PT Maja Agung Latexindo Tbk ranks worse than 98.05% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PT Maja Agung Latexindo Tbk's enterprise value is Rp444,944 Mil.
PT Maja Agung Latexindo Tbk's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was Rp1,530 Mil. Therefore, PT Maja Agung Latexindo Tbk's EV-to-EBITDA for today is 290.81.
The historical rank and industry rank for PT Maja Agung Latexindo Tbk's EV-to-EBITDA or its related term are showing as below:
ISX:SURI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5322.76 Med: 63.77 Max: 6434.03
Current: 290.81
During the past 6 years, the highest EV-to-EBITDA of PT Maja Agung Latexindo Tbk was 6434.03. The lowest was -5322.76. And the median was 63.77.
ISX:SURI's EV-to-EBITDA is ranked worse than 98.05% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.95
vs ISX:SURI: 290.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PT Maja Agung Latexindo Tbk (ISX:SURI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Maja Agung Latexindo Tbk's PE Ratio (TTM) for today is calculated as:
PT Maja Agung Latexindo Tbk's share price for today is Rp78.00.
PT Maja Agung Latexindo Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp0.145.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:SURI vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, PT Maja Agung Latexindo Tbk's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Maja Agung Latexindo Tbk EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT Maja Agung Latexindo Tbk's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Maja Agung Latexindo Tbk's EV-to-EBITDA falls into.
PT Maja Agung Latexindo Tbk's current Enterprise Value is Rp444,944 Mil.
PT Maja Agung Latexindo Tbk's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp1,530 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Maja Agung Latexindo Tbk (ISX:SURI) has a EV-to-EBITDA of 290.81 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Maja Agung Latexindo Tbk. This is 356% above median its historical median of 63.77. According to the industry distribution chart, PT Maja Agung Latexindo Tbk ranks #503 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 98.1%.
Is PT Maja Agung Latexindo Tbk's EV-to-EBITDA too high?
PT Maja Agung Latexindo Tbk's current EV-to-EBITDA of 290.81 is 356% above median its 10-year median of 63.77. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.95. PT Maja Agung Latexindo Tbk's value of 290.81 is 1845.2% above this industry median. Based on the distribution chart, PT Maja Agung Latexindo Tbk ranks #503 out of 513 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PT Maja Agung Latexindo Tbk has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Maja Agung Latexindo Tbk's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PT Maja Agung Latexindo Tbk ranks #503 out of 513 companies for EV-to-EBITDA. This places PT Maja Agung Latexindo Tbk in the lower half of its industry. The industry median EV-to-EBITDA is 14.95. PT Maja Agung Latexindo Tbk's value of 290.81 is 1845.2% above this benchmark. While the company's 10-year median is 63.77 vs. the industry median of 14.95, PT Maja Agung Latexindo Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.95, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Maja Agung Latexindo Tbk's current EV-to-EBITDA of 290.81 is 1845.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Maja Agung Latexindo Tbk. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Maja Agung Latexindo Tbk's current EV-to-EBITDA is 290.81, which is 356% above median its own 10-year median of 63.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Maja Agung Latexindo Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Maja Agung Latexindo Tbk (ISX:SURI) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp107.24, compared to a current price of Rp78.00 — trading 27.3% below its estimated fair value. The current EV-to-EBITDA is 290.81, which is 356% above median its 10-year median of 63.77 and 1845.2% above the Medical Devices & Instruments industry median of 14.95. PT Maja Agung Latexindo Tbk's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PT Maja Agung Latexindo Tbk (ISX:SURI), the current EV-to-EBITDA is 290.81 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Maja Agung Latexindo Tbk (ISX:SURI) Overvalued in 2026?
Based on GuruFocus' analysis, PT Maja Agung Latexindo Tbk stock appears to be undervalued.
The current stock price of Rp78.00 is trading 27.3% below its estimated GF Value™ of Rp107.24.
GuruFocus considers PT Maja Agung Latexindo Tbk to be Modestly Undervalued.
Key valuation signals for ISX:SURI:
EV-to-EBITDA: 290.81 (356% above median its 10-year median of 63.77)
GF Value™: Rp107.24 vs. price of Rp78.00 (27.3% below fair value)
Industry Position: 1845.2% above the Medical Devices & Instruments median (#503 of 513)
No single metric tells the full story. See the ISX:SURI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Maja Agung Latexindo Tbk specializes in the production of latex gloves, made from natural rubber, and is a primary choice in the medical and industrial sectors. The company's business includes business of making rubber goods for health support needs, such as contraceptive gloves (birth control)/ condoms, pacifiers and compresses, medical rubber gloves, and urinary catheters (folley catheter). Its segments include Gloves and Concentrated latex.
53GF Score
Get the complete analysis for ISX:SURI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SURI has been successfully added to your 
